Imugene (ASX:IMU) Presentation, FNN Investor Event, May 2019, Sydney

Company Presentations

Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong presents on trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vaccines and outlook for 2H19 at FNN's Investor Event.

Key points:

  • An emerging leader in cancer immuno-oncology
  • Strong preliminary results from ongoing clinical trials
  • Robust pipeline of B-cell vaccines targeting high potential areas
  • Fully funded to progress clinical program
  • Best in class leadership team with a track record in drug development
  • Active market with numerous commercialisation opportunities in the sector
  • Promising Phase 1 clinical trial results

For more, watch MD & CEO Leslie Chong present.